380
Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorec-
tal cancers. Science. 2006;314:268–74.
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N
Engl J Med. 2011;365:1273–83.
Slobbe P, Poot AJ, Windhorst AD, van Dongen G. PET imaging with small-molecule tyrosine
kinase inhibitors: TKI-PET. Drug Discov Today. 2012;17:1175–87.
Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as a therapeutic target in
human acute myeloid leukaemia. Nature. 2012;485:260–3.
Snozek CL, O’Kane DJ, Algeciras-Schimnich A. Pharmacogenetics of solid tumors. directed ther-
apy in breast, lung, and colorectal cancer. J Mol Diagn. 2009;11:381–9.
Song R, Liu Q, Hutvagner G, et al. Rule discovery and distance separation to detect reliable
miRNA biomarkers for the diagnosis of lung squamous cell carcinoma. BMC Genomics
2014;15 Suppl 9:S16.
Sos ML, Fischer S, Ullrich R, et al. Identifying genotype-dependent effi cacy of single and com-
bined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A.
2009;106:18351–6.
Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. NEJM. 2009;360:790–800.
Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma refl ects
cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013;110:4009–14.
Spencer SL, Gaudet S, Albeck JG, et al. Non-genetic origins of cell-to-cell variability in TRAIL-
induced apoptosis. Nature. 2009;459:428–32.
Stamatakos GS, Antipas VP, Uzunoglu NK. Simulating chemotherapeutic schemes in the indi-
vidualized treatment context: the paradigm of glioblastoma multiforme treated by temozolo-
mide in vivo. Comput Biol Med. 2006;36:1216–34.
Su Z, Dannull J, Yang BK, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-
specifi c CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J
Immunol. 2005;174:3798–807.
Tagliabue E, Balsari A, Campiglio M, Pupa SM. HER2 as a target for breast cancer therapy. Expert
Opin Biol Ther. 2010;10:711–24.
Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer
patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine
kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007;99:838–46.
Takahashi N, Yamada Y, Furuta K, et al. Serum levels of hepatocyte growth factor and epiregulin
are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type meta-
static colorectal cancer. Br J Cancer. 2014;110:2716–27.
Tandon P, Farahani K. NCI image-guided drug delivery summit. Cancer Res. 2011;71:314–7.
Teschendorff AE, Miremadi A, Pinder SE, et al. An immune response gene expression module
identifi es a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol.
2007;8:R157.
Thaxton CS, Elghanian R, Thomas AD, et al. Nanoparticle-based bio-barcode assay redefi nes
“undetectable” PSA and biochemical recurrence after radical prostatectomy. Proc Natl Acad
Sci U S A. 2009;106:18437–42.
The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon
and rectal cancer. Nature. 2012;487:330–7.
The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma.
Nature. 2011;474:609–15.
The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de
novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.
Tian Q, Price ND, Hood L. Systems cancer medicine: towards realization of predictive, preventive,
personalized, and participatory (P4) medicine (key symposium). J Intern Med. 2012;271:
111–21.
Timmerman JM, Vose JM, Czerwinski DK, et al. Tumor-specifi c recombinant idiotype immunisa-
tion after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk
Lymphoma. 2009;50:37–46.
10 Personalized Therapy of Cancer